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SUMMARY: 
Here we present a screening method for membrane-bound pyrophosphatase (from Thermotoga 
maritima) inhibitors based on the molybdenum blue reaction in a 96 well plate format. 
 
ABSTRACT: 
Membrane-bound pyrophosphatases (mPPases) are dimeric enzymes that occur in bacteria, 
archaea, plants, and protist parasites. These proteins cleave pyrophosphate into two 
orthophosphate molecules, which is coupled with proton and/or sodium ion pumping across the 
membrane. Since no homologous proteins occur in animals and humans, mPPases are good 
candidates in the design of potential drug targets. Here we present a detailed protocol to screen 
for mPPase inhibitors utilizing the molybdenum blue reaction in a 96 well plate system. We use 
mPPase from the thermophilic bacterium Thermotoga maritima (TmPPase) as a model enzyme. 
   
This protocol is simple and inexpensive, producing a consistent and robust result. It takes only 
about one hour to complete the activity assay protocol from the start of the assay until the 
absorbance measurement. Since the blue color produced in this assay is stable for a long period 
of time, subsequent assay(s) can be performed immediately after the previous batch, and the 
absorbance can be measured later for all batches at once. The drawback of this protocol is that 
it is done manually and thus can be exhausting as well as require good skills of pipetting and time 
keeping. Furthermore, the arsenite-citrate solution used in this assay contains sodium arsenite, 
which is toxic and should be handled with necessary precautions. 
 
INTRODUCTION: 
Approximately 25% of the total cellular proteins are membrane proteins and about 60% of them 
are drug targets1,2. One of the potential drug targets3, membrane-bound pyrophosphatases 
(mPPases), are dimeric enzymes that pump proton and/or sodium ion across the membrane by 
hydrolysis of pyrophosphate into two orthophosphates4. mPPases can be found in various 
organisms5 such as bacteria, archaea, plants, and protist parasites, with the exception of humans 
and animals4. In protist parasites, for example Plasmodium falciparum, Toxoplasma gondii and 
Trypanosoma brucei, mPPases are essential for the parasite virulence6 and knockout of this 
expression in the parasites lead to failure in maintaining intracellular pH upon exposure to the 
external basic pH7. Due to their importance and lack of homologous protein present in 
vertebrates, mPPases can be considered as potential drug targets for protistal diseases3. 
 
The in vitro screening of mPPase inhibitors in this work is based on a TmPPase model system. 
TmPPase is a sodium ion pumping and potassium ion dependent mPPase from T. maritima and 
has its optimum activity at 71 °C8. Benefits of this enzyme are for example its ease in production 
and purification, good thermal stability and high specific activity. TmPPase shows both high 
similarity in addition to the complete conservation of the position as well as identity of all 
catalytic residues to the protist mPPases3,9 and to the solved structure of Vigna radiata10 mPPase. 
The available structures of TmPPase in different conformations are also useful for structure-
based drug design experiment (as virtual screening and de novo design). 
 
Here we report a detailed protocol for screening of TmPPase inhibitors in a 96 well plate format 
(Figure 1). The protocol is based on the colorimetric method of the molybdenum blue reaction, 
which was first developed by Fiske and Subbarow11. This method involves the formation of 12-
phosphomolybdic acid from orthophosphate and molybdate under acidic conditions, which is 
then reduced to give characteristic blue-colored phosphomolybdenum species12. 
 
PROTOCOL: 
 
1. Protein preparation 
 
NOTE: The expression and purification of TmPPase has been described elsewhere13. 
 
   
1.1. Prepare 10 mL of the reactivation buffer solution containing 20 mM 2-(N-
morpholino)ethanesulfonic acid (MES) pH 6.5, 3.5% (v/v) glycerol, 2 mM dithiothreitol (DTT), and 
0.05% dodecyl maltoside (DDM). 
 
1.2. Prepare 10 mL of the reaction mixture containing 200 mM Tris-Cl pH 8.0, 8.0 mM MgCl2, 333 
mM KCl, and 67 mM NaCl. 
 
NOTE: Mg2+ is required to chelate the pyrophosphate as the substrate of mPPase, K+ is required 
to increase the enzyme activity as TmPPase is a potassium dependent mPPase, and Na+ is needed 
for the enzyme activity during sodium ion translocation by TmPPase. 
 
1.3. Prepare 30 mg/mL liposomes for enzyme reactivation. 
 
1.3.1. Add 0.3 g of L-ɲ-phosphatidylcholine from soybean to 10 mL of 20 mM Tris-HCl pH 8.0 with 
1 mM DTT. 
 
1.3.2. Sonicate the liposome with 1 s pulse interval for 1 min, pause for 1 min, and repeat until 
the solution becomes transparent yellow. 
 
1.3.3. Aliquot the liposomes, freeze in liquid nitrogen and store at -80 °C until used. 
 
1.4. Reactivate the enzyme. 
 
1.4.1. Mix 40µL of the liposomes solution with 22.5 µL of 20% DDM. 
 
1.4.2. Heat the mixture at 55 °C for 15 min and allow it to cool to room temperature. 
 
1.4.3. Add 36.5 µL of the reactivation buffer solution, mix, and add 1 µL of concentrated protein 
(13 mg/mL) to make a total concentration of 0.13 mg/mL. 
 
NOTE: Protein is usually frozen in 10 µL aliquots after purification and thawed on ice before use. 
 
1.5. Take 20 µL of the reactivated enzyme and add to 1,480 µL of the reaction mixture, then mix 
gently.  
 
NOTE: The addition of the reactivated enzyme to the reaction mixture should be performed just 
before it is used. 
 
2.  Compound preparation 
 
2.1. Dissolve the compounds in dimethyl sulfoxide (DMSO) to make stock solutions of 25о100 
mM in 50о200 µL, based on the availability of the compounds.  
 
   
NOTE: All compounds used here (Figure 2A) have been published previously9. If the compound 
solubility is low, the stock concentration can be adjusted accordingly.  
 
2.2. Prepare three different concentrations of each compound in water. 
 
2.2.1. Dilute the stock solution with water to 1 mL in microtubes to give 2 µM, 10 µM and 100 
µM for soluble compounds, or alternatively 2 µM, 10 µM and 40 µM for sparingly soluble 
compounds. 
 
2.2.2. Vortex the compound solution instantly after dilution of the stock solution for proper 
mixing. 
 
2.3. Check the possible compound aggregation in the assay using a nephelometer.  
 
NOTE: This was studied as triplicates in three concentrations (1 µM, 5 µM and 20 µM) and 
normalized to the blank in a 96 well plate. 
 
2.3.1. Dispense 75 µL of the reaction mixture into each well using a multichannel pipette. 
 
2.3.2. Add 75 µL of each compound (for the blank, use 75 µL of water instead) and mix by 
pipetting up and down 5x. 
 
2.3.3. Measure the turbidity of each well at 300 V using a microplate nephelometer. 
 
3. Reagents for the assay preparation 
 
3.1. Prepare the arsenite-citrate solution. 
 
3.1.1. Weigh 5 g of sodium arsenite and 5 g of trisodium citrate dihydrate.  
 
CAUTION: Sodium arsenite is toxic, thus use proper protective equipment and handle with special 
care. As precaution, do not handle before all necessary safety precautions have been read and 
understood. Handle only in a fume hood in order not to inhale dust/vapors of the compound or 
its solution(s). If inhaled, move to fresh air and obtain medical attention. Wear appropriate 
chemical safety goggles, protective gloves and clothing to avoid ingestion and eye/skin contact. 
If swallowed, call immediately a poison center or doctor/physician. If it gets on the skin or in the 
eye(s), wash with plenty of water and obtain medical attention. 
 
3.1.2. Dissolve into 100 mL of water. 
 
3.1.3. Add 5 mL of glacial acetic acid, mix, and add water to 250 mL. 
 
3.1.4. Store at room temperature protected from light.  
 
   
NOTE: The solution is stable for more than a year. 
 
3.2. Prepare solution A and solution B. 
 
3.2.1. For solution A, add 10 mL of ice cold 0.5 M HCl to 0.3 g of ascorbic acid. Dissolve the 
ascorbic acid by vortexing.  
 
3.2.2. For solution B, add 1 mL of ice cold water to 70 mg of ammonium heptamolybdate 
tetrahydrate and vortex to dissolve. 
 
NOTE: Store both solutions on ice until use. For the consistency of the assay result, both solutions 
can be stored on ice for a maximum of a week. 
 
3.3. Prepare the phosphate (Pi) standard with the concentration of 0 µM, 62.5 µM, 250 µM and 
500 µM for calibration. 
 
3.3.1. Add 0 µL, 25 µL, 50 µL, and 100 µL of 5 mM Na2HPO4 dihydrate to four microtubes 
containing 370 µL of the reaction mixture. 
 
3.3.2. Top up to 1 mL with water. 
 
4. Activity assay for one 96 well plate 
 
NOTE: See Figure 1 for the schematic workflow of the assay. 
 
4.1. Add 1 mL of solution B to 10 mL of solution A, mix by vortexing and store the solution on ice.  
 
NOTE: This solution should be transparent and yellow. Keep solution A + B on ice for at least 30 
min prior to use. However, use the solution within 3 h as it will go bad after long-term storage. 
 
4.2. Add 40 µL of 0 µM, 62.5 µM, 250 µM and 500 µM Pi standard to the tube strips in triplicate 
using a multichannel pipette.  
 
NOTE: The reaction mixture with no Pi added will be used as a blank. 
 
4.3. Add 25 µL of compound solution to the tube strips using a multichannel pipette. 
 
NOTE: Each compound has three different concentrations in triplicate which is enough for initial 
estimation of the half maximal inhibitory concentration (IC50). For a more accurate IC50 
determination, eight different compound concentrations can be used. For the uninhibited 
enzyme the compound solution is replaced with equal amount of water. As positive controls 2.5 
µM, 25 µM, and 250 µM of imidodiphosphate (IDP) sodium salt were used. 
 
   
4.4. Add 15 µL of mPPase solution mixture to the tube strips (except to the tubes containing Pi 
standard) using a multichannel pipette. 
 
4.5. Seal the tube strips with an adhesive sealing sheet. Cut the sealing sheet to separate each 
tube strip. 
 
4.6. Pre-incubate the samples for 5 min at 71 °C. Place the samples on the heating block with 20 
s interval between each strip in order to minimize the time consumption during the subsequent 
steps. 
 
4.7. For each strip, open the adhesive sealing. Add 10 µL of 2 mM sodium pyrophosphate dibasic 
using a multichannel pipette and mix by pipetting up and down for 5x. Seal the tube strip again 
using the same sealing.  
 
NOTE: This step might initially be difficult to accomplish in 20 s; however, it will become easier 
after some assays. 
 
4.8. Incubate at 71 °C for 5 min. 
 
4.9. Place the samples on the cooling apparatus with 20 s interval between each strip. Let them 
cool for 10 min but centrifuge each strip briefly after 5 min of cooling, to decant water drops 
under the sealing sheet, then put it back to the cooling apparatus and remove the sealing.  
 
NOTE: The cooling apparatus can simply be made by placing a 96 well PCR plate on a polystyrene 
Petri dish (size 150 mm x 15 mm) filled with water and frozen for at least 1 h. The apparatus 
should be taken out from the freezer about 5 min prior to the beginning of the assay. Do not take 
out the cooling apparatus right before sample cooling as it will freeze the reaction mixture and 
hinder color development. 
 
4.10. After 10 min of cooling, add 60 µL of solution A + B, mix by pipetting up and down for 5x 
and keep the tube strips on the cooling apparatus for 10 min. 
 
4.11. Add 90 µL of the arsenite-citrate solution and keep at room temperature for at least 30 min 
to produce a stable blue color.  
 
CAUTION: Due to its toxicity all solutions containing sodium arsenite should be handled with 
extra care at all time. Thus, the addition of arsenite-citrate solution should be done in a fume 
hood. 
 
4.12. Dispense 180 µL of each reaction mixture into a clear 96 well polystyrene microplate. 
 
4.13. Measure the absorbance of each well at 860 nm using a microplate spectrophotometer. 
 
5. Result analysis 
   
 
5.1. Average the triplicates of each sample and the Pi standards. Then subtract with the blank to 
eliminate the background signal. 
 
5.2. Make a calibration curve by plotting the absorbance (A860) values against the amount of Pi 
standard (nmol) and perform a linear regression to obtain the trendline function using the 
following formula:  
 ܣ଼଺଴ ൌ ݉ ௜ܲ ൅ 
 
5.3. Calculate the phosphate amount (nmol) released from the enzymatic reaction based on the 
linear regression formula above. 
 
5.4. Calculate the specific activity using the following formula: 
 ܵ݌݂݁ܿ݅݅ܿܽܿݐ݅ݒ݅ݐݕሺܵܣሻ ൌ ݊ ௜ܲݐ  ? ்݉௠௉௉௔௦௘ 
 
where nPi is the amount of phosphate released from the reaction (nmol), t is the reaction time 
(min), and mTmPPase is the amount of the pure TmPPase used in the assay (mg). 
 
5.5. Calculate the percent activity for each inhibitor concentration using the following formula: 
  ?ܣܿݐ݅ݒ݅ݐݕ ൌ ܵܣ௜ܵܣ௨௡ ൈ  ? ? ? ? 
 
where SAi is the specific activity of a sample with inhibitor and SAun is the specific activity of the 
uninhibited sample. 
 
5.6. Calculate the logIC50 (estimate) and IC50 (estimate) with a nonlinear regression fit from the 
four-parameter dose-response curve using the following formula: 
 ܻ ൌ ܤ݋ݐݐ݋݉ ൅ሺܶ݋݌ െ ܤ݋ݐݐ݋݉ሻȀሺ ? ൅ ? ?ሺሺ௟௢௚ூ஼ఱబି௑ሻכு௜௟௟ௌ௟௢௣௘ሻሻ 
 
where X is log of concentration (µM), Y is activity (%), Top and Bottom are plateaus in the same 
unit as Y (100% and 0%, respectively), logIC50 has the same log units as X, and HillSlope = slope 
factor or hill slope, which is unitless.  
 
NOTE: Software (Table of Materials) is used for the fitting. Use the concentration of 0.01 µM 
(instead of 0.00 µM) for the sample without inhibitor as the logarithm of zero is not defined. 
 
REPRESENTATIVE RESULTS: 
In this protocol, eight compounds (1о8) were tested (Figure 2A) together with IDP, a common 
inhibitor of pyrophosphatases, as a positive control. Each compound was tested at three different 
   
concentrations (1 µM, 5 µM and 20 µM) in triplicate. The workflow of the screening is depicted 
in Figure 1, starting from sample and reagent preparation until the absorbance measurement at 
860 nm. 
 
At the end of this protocol, after the addition of solution A + B and arsenite-citrate, the solutions 
develop a stable blue color with the maximum absorption at 709 nm and 860 nm14 due to the 
complex formation of phosphate ions with molybdate that can be observed and shows the 
occurrence of the enzymatic reaction. For this experiment, we use the absorbance at 860 nm for 
the measurement of Pi amount released as it has better detection limit and sensitivity compared 
to the absorbance at 709 nm15. The blue color is fully developed in 30 min of incubation at room 
temperature and stable for at least 5 h14. The assay has the sensitivity down to Pi concentration 
of 10 µM and the absorbance is linear over a concentration range of 10о800 µM14. In the 
representative result here, wells E1оE3 (Figure 2C) contain the reaction mixture without inhibitor 
and the blue solution can be observed at the end of the assay. This can also be observed at low 
compound concentrations where complete inhibition has not been reached, as in wells F1оF3 for 
IDP and wells A4оA6 for compound 1 (ATC, a recently known uncompetitive inhibitor of 
TmPPase9) at the concentration of 2.5 µM and 1 µM, respectively. The higher concentration of 
IDP and compound 1, the less to no blue color can be observed (G1оG3 and H1оH3 for IDP and 
B4оB6 and C4оC6 for compound 1) indicating inhibition of the enzymatic activity. All three 
concentrations of non-inhibiting compounds (2, 3, and 8) displayed the same blue color intensity 
as wells E1оE3 without any inhibitor (Figure 2C). 
 
After the absorbance measurement at 860 nm, the data can be processed and analyzed (see 
protocol section 5). Figure 2D shows the calibration plot of Pi standard with its linear fitting (y = 
0.0576x + 0.0019; r2 = 0.999). Figure 3 shows the plot of enzymatic activity (%) against the 
concentration of each tested compound. For compounds with inhibition activity, a nonlinear 
curve fitting is also shown. IDP, used as a positive control, clearly shows a decrease in activity at 
higher concentration. The IC50 (estimate) calculated based on three different concentrations is 
88.2 µM (Table 1), which is similar to the previous measurement (80.0 µM) with eight 
concentration points14. Compounds 1, 4, 5, 6, and 7 showed a similar trend as IDP since the 
concentration increased with the IC50 (estimate) of approximately 1.3 µM, 7.4 µM, 19.0 µM, 37.4 
µM, and 156.1 µM, respectively (Table 1). For compounds 2, 3, and 8 no reduction in activity or 
inhibition can be observed at the assay concentrations. An additional assay with eight 
concentration points can be done to generate precise IC50. Figure 4 shows the inhibition curve 
for compounds 1, 5, 6, 7 and 8 with an IC50 of 1.7 µM, 21.4 µM, 58.8 µM, 239.0 µM and >500 µM, 
respectively9. 
 
FIGURE AND TABLE LEGENDS: 
 
Figure 1: A schematic workflow of TmPPase inhibition assay in a 96 well plate format. The red 
numbering shows the steps of the assay according to the protocol and the blue arrows show the 
interval order. 
 
   
Figure 2: Samples, their arrangement and color development in a 96 well plate. (A) The 
structures of compounds 1о8 used for the assay. The inhibition activity of these compounds has 
been reported in Vidilaseris et al.9. (B) Sample arrangement. (C) Color development, 30 min after 
the addition of arsenite-citrate solution. The concentrations of control inhibitor (IDP) and 
samples used, arranged from the top to the bottom, are 2.5 µM, 25 µM, and 250 µM 
concentration and 1 µM, 5 µM, and 20 µM concentration, respectively. The intensity of the blue 
color corresponds to the amount of Pi released due to the enzymatic reaction and the lack of 
color corresponds to no enzymatic reaction. (D) Calibration curve for Pi standard (nmol) against 
A860 with linear fitting (y = 0.0576x + 0.0019; r2 = 0.999). 
 
Figure 3: Curve of the TmPPase percent activity for three different inhibitor concentrations. 
The nonlinear regression curves to calculate the IC50 (estimate) are shown for IDP as well as for 
compounds 1, 4, 5, 6 and 7 but not for compounds 2, 3, and 8 as they were not inhibiting TmPPase 
activity at the assay concentrations. The logIC50 and IC50 (estimate) of each compound is shown 
in Table 1. All data are shown as mean ± SD with three replicates. 
 
Figure 4: Inhibition curve from eight concentration points of compounds 1, 5, 6, 7 and 8. This 
figure is taken from Vidilaseris et al.9 with slight modification. All data are shown as mean ± SD 
with three replicates. 
 
Table 1: LogIC50 and IC50 (estimate) of IDP and compounds 1о8 based on the data from Figure 
3. 
 
DISCUSSION: 
Here we report a detailed protocol for simple screening of inhibitors for membrane-bound 
pyrophosphatase from T. maritima in a 96 well plate format based on Vidilaseris et al.14. This 
protocol is inexpensive and based on 12-phosphomolybdic acid, which is formed from 
orthophosphate and molybdate under acidic conditions and reduced to phosphomolybdenum 
species with a distinct blue color12. This method is preferred over other protocols, such as the 
more sensitive malachite green assay16, because this method does not show interference in the 
presence of high phospholipid concentration which is required for TmPPase reactivation14.  
 
The workflow of the screening protocol is depicted in Figure 1 and this process can be fully 
accomplished in 1 h. This protocol is optimized for TmPPase with the optimal working 
temperature at 71 °C and a 5 min reaction time. As water will evaporate at this temperature from 
the reaction mixture, an adhesive sealing sheet (sliced to fit and cover the strips) is applied to 
prevent evaporation14 and the evaporated water is simply recollected with centrifugation. The 5 
min incubation time is chosen as it is still in the linear range of the enzymatically released 
phosphate and sufficient for reliable screening14. In this protocol, the timing and pipetting skills 
are important factors to obtain a good and reliable result. Addition of reagents during the assay 
with 20 s interval between strips is an optimized timing option for ease of performing the 
subsequent steps. 
 
   
For different mPPases, the optimum temperature and incubation time should be determined 
separately prior to use in the inhibition assay. The enzyme reactivation protocol above is 
optimized for TmPPase and other mPPases might need a different reactivation protocol. For 
example, DDM should not be added for reactivation of mPPase from Pyrobaculum aerophilum as 
it will decrease its enzymatic activity17. As the enzyme will become less active if prepared well in 
advance, the addition of reactivated enzyme should be added to the reaction mixture shortly 
before the assay is initiated. After addition of the arsenite-citrate solution the reaction product 
is stable for at least 5 h14. Therefore, the next batch of the assay can be performed immediately, 
and the absorbance measurement can be done later to all batches at once. 
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Transfer the solution to 96 well-plate
Read the absorbance at 860 nm
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